Search | Clinical Trials Finder

Conditions: BRCA-Mutated Ovarian Carcinoma, BRIP1 Gene Mutation, MSH2 A636P, MLH1 Gene Mutation, MSH6 Gene Mutation, PMS2 Gene Mutation, EPCAM, RAD51C Gene Mutation
Interventions: CASCADE genetic screening; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Ovarian Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation, Serous Tubal Intraepithelial Carcinoma, Early Detection of Ovarian Cancer
Interventions: Galleri Multi-Cancer Early Detection (MCED) Blood Test; Device
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 35 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2039
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Conditions: Hereditary Breast and Ovarian Cancer
Interventions: Genetic Counseling and Testing YouTube Video; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Alexandria, Virginia

Conditions: Breast Cancer, Ovarian Cancer
Interventions: AZ2281 + Carboplatin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2037
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Pancreatic Cancer
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Hereditary Breast and Ovarian Cancer Syndrome
Interventions: Culturally-Targeted Video, FORCE Fact Sheet; Behavioral · Other
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Alexandria, Virginia • Arlington, Virginia + 1 more

Conditions: Hereditary Breast and Ovarian Cancer
Interventions: Breast Cancer Genetics Referral Screening Tool 3.0, Standard Handout, Physician Notification, Automatic Follow-Up by Genetic Counseling Staff; Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 665 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome
Interventions: Best Practice, Biospecimen Collection, Counseling, Discussion, Genotyping, Molecular Risk Assessment, Questionnaire Administration; Other · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Columbus, Ohio • Salt Lake City, Utah

Conditions: Deleterious BARD1 Gene Mutation, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Deleterious BRIP1 Gene Mutation, Deleterious EPCAM Gene Mutation, Deleterious MLH1 Gene Mutation, Deleterious MSH2 Gene Mutation, Deleterious MSH6 Gene Mutation, Deleterious PALB2 Gene Mutation, Deleterious PMS2 Gene Mutation, Deleterious RAD51C Gene Mutation, Deleterious RAD51D Gene Mutation, Hereditary Breast and Ovarian Cancer Syndrome, Premenopausal
Interventions: Laboratory Biomarker Analysis, Oophorectomy, Quality-of-Life Assessment, Salpingectomy, Salpingo-Oophorectomy; Other · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 30 Years to 50 Years · Female only
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2041
U.S. locations: 9
States / cities: Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 5 more

Conditions: Ovarian Neoplasm, Cancer Genetics, Breast Cancer
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: Self Affirmation (SA), Control; Behavioral
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Hereditary Breast and Ovarian Cancer, Lynch Syndrome
Interventions: Online modality, Genetic counselor follow-up; Behavioral
Lead sponsor: Boston University; Other
Eligibility: 40 Years and older · Female only
Enrollment: 926 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Hereditary Breast Cancer
Interventions: Telephone Genetic Counseling; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 21 Years to 90 Years · Female only
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Hackensack, New Jersey • Alexandria, Virginia + 1 more

Conditions: Fallopian Tube Carcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Ovarian Carcinoma, Primary Peritoneal Carcinoma
Interventions: Evaluation of Cancer Risk Factors, Medical Chart Review, Study of Socioeconomic and Demographic Variables; Procedure · Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 30 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)
Interventions: counseling intervention, educational intervention, survey administration, psychosocial assessment and care, supportive care; Other · Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 8 Years to 120 Years · Female only
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts

Conditions: Breast Cancer, Hereditary Breast and Ovarian Cancer
Interventions: Not listed
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: Not listed
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2026
U.S. locations: 11
States / cities: Hays, Kansas • Kansas City, Kansas • Overland Park, Kansas + 4 more

Conditions: Hereditary Breast and Ovarian Cancer Syndrome, Osteoporosis, Ovarian Carcinoma
Interventions: Laboratory Biomarker Analysis, Zoledronic Acid; Other · Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 95
States / cities: Scottsdale, Arizona • Tucson, Arizona • Burbank, California + 76 more

Conditions: Hereditary Breast/Ovarian Cancer (brca1, brca2), Lynch Syndrome, Genetic Variation, HBOC Syndrome, Hereditary Cancer Syndromes
Interventions: Patient Centered Clinical Decision Support (PC-CDS); Other
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 2,488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
Interventions: Administration of ceralasertib, Administration of ceralasertib in combination with olaparib, Administation of ceralasertib in combination with durvalumab, Administration of ceralasertib monotherapy, Administration of ceralasertib and olaparib, Administration of ceralasertib and durvalumab, Administration of ceralasertib in combination with AZD5305, Administration of ceralasertib in combination with carboplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 8
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 4 more

Conditions: Breast Cancer, Hereditary Breast and Ovarian Cancer Syndrome, Breast Implant; Complications
Interventions: Insertion of Tissue Expander with Fluid Reservoir; Device
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome
Interventions: Telemedicine, Face-to-Face; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 4
States / cities: Henderson, North Carolina • Laurinburg, North Carolina • Lumberton, North Carolina + 1 more

Conditions: Adult Solid Neoplasm, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Hereditary Breast and Ovarian Cancer Syndrome
Interventions: Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Veliparib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 7
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 3 more

Conditions: Hereditary Breast and Ovarian Cancer
Interventions: Questionnaires, Blood Draw and Baseline Questionnaire; Other
Lead sponsor: University of Southern California; Other
Eligibility: Not listed
Enrollment: 1,511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 2
States / cities: Los Angeles, California • Stanford, California

Search by objective public record fields.

Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome

Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants

Enhancing At-risk Latina Women's Use of Genetic Counseling for Hereditary Breast and Ovarian Cancer

AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer

Familial Investigations of Childhood Cancer Predisposition

Validation of a Mouse Model of Pancreatic Carcinogenesis

Enhance the Use of Genetic Counseling and Testing in Latinas

Identification and Referral of Women at Risk for Hereditary Breast/Ovarian Cancer

Clinical Impact of Enhanced Risk Assessments in Women With a BRCA1/2 Mutation, CARE Study

Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations

Family Communication of Hereditary Breast and Ovarian Cancer Risk Among African Americans

Is it Feasible?: Self-Affirmation for Hereditary Breast and Ovarian Cancer Genetic Counseling

Scalable Communication Modalities for Returning Genetic Research Results

Testing a Culturally Adapted Telephone Genetic Counseling Intervention

Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199

Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children

Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry

Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries

Patient Centered Clinical Decision Support for Hereditary Cancer Syndromes

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Tissue Expansion in Breast Reconstruction Without Drains

Telemedicine vs. Face-to-Face Cancer Genetic Counseling

Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer

Cancer Genetics Hereditary Cancer Panel Testing